ZA979706B - Nicotinic agents in addiction theraphy - Google Patents

Nicotinic agents in addiction theraphy

Info

Publication number
ZA979706B
ZA979706B ZA979706A ZA979706A ZA979706B ZA 979706 B ZA979706 B ZA 979706B ZA 979706 A ZA979706 A ZA 979706A ZA 979706 A ZA979706 A ZA 979706A ZA 979706 B ZA979706 B ZA 979706B
Authority
ZA
South Africa
Prior art keywords
theraphy
addiction
nicotinic agents
nicotinic
agents
Prior art date
Application number
ZA979706A
Other languages
English (en)
Inventor
Brian Thomas O'neill
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA979706B publication Critical patent/ZA979706B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
ZA979706A 1996-10-30 1997-10-29 Nicotinic agents in addiction theraphy ZA979706B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2880496P 1996-10-30 1996-10-30

Publications (1)

Publication Number Publication Date
ZA979706B true ZA979706B (en) 1999-04-29

Family

ID=21845528

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA979706A ZA979706B (en) 1996-10-30 1997-10-29 Nicotinic agents in addiction theraphy

Country Status (17)

Country Link
US (2) US6235734B1 (fr)
EP (1) EP0937077B1 (fr)
JP (2) JP3621707B2 (fr)
AP (1) AP9701125A0 (fr)
AR (1) AR008901A1 (fr)
AT (1) ATE326468T1 (fr)
AU (1) AU4394897A (fr)
DE (1) DE69735891T2 (fr)
ES (1) ES2264169T3 (fr)
GT (1) GT199700115A (fr)
HR (1) HRP970567A2 (fr)
ID (1) ID18741A (fr)
MA (1) MA26445A1 (fr)
PA (1) PA8440201A1 (fr)
TN (1) TNSN97168A1 (fr)
WO (1) WO1998018798A1 (fr)
ZA (1) ZA979706B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6717030B2 (en) * 1998-07-06 2004-04-06 The Regents Of The University Of California Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US20020010192A1 (en) * 2000-06-02 2002-01-24 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
DE60228478D1 (de) 2001-11-30 2008-10-02 Pfizer Prod Inc Aryl-annellierte azapolyzyklische verbindungen
SE0104463D0 (sv) * 2001-12-29 2001-12-29 Carlbiotech Ltd As Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
WO2005000806A2 (fr) * 2003-06-10 2005-01-06 Georgetown University Ligands pour les recepteurs de l'acetylcholine nicotinique, et procedes de production et d'utilisation de ces ligands
EP1648893B1 (fr) 2003-07-21 2009-09-23 Pfizer Products Inc. Composes azapolycycliques fusionnes avec heteroaryle pour reduire la dependance a la nicotine
US20050234024A1 (en) * 2004-04-14 2005-10-20 Clarke David E Materials and methods for the treatment of ulcerative colitis
US7135933B2 (en) * 2004-09-29 2006-11-14 Intelliserv, Inc. System for adjusting frequency of electrical output pulses derived from an oscillator
ATE395348T1 (de) * 2004-12-07 2008-05-15 Pfizer Prod Inc 1,2,3,3a;8,8a-hexahydro-2,7a- diazacyclopenta(a)inden-7-onderivate, die sich an neuronale nikotinische acetylcholinspezifische rezeptorstellen binden und zur modulation der cholinergen funktion und zur behandlung von suchterkrankungen eignen
US20060211649A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of cytisine for enhancing physical performance
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
WO2007100430A2 (fr) * 2006-01-27 2007-09-07 Yale University Analogues de cystisine et d'acétylcholine et procédés de traitement des troubles de l'humeur
WO2007115092A2 (fr) * 2006-03-29 2007-10-11 Georgetown University Dérivés de cytisine substitués en position 10 et leurs procédés d'utilisation
US7404725B2 (en) * 2006-07-03 2008-07-29 Hall David R Wiper for tool string direct electrical connection
US8061443B2 (en) * 2008-04-24 2011-11-22 Schlumberger Technology Corporation Downhole sample rate system
MX368365B (es) * 2009-12-22 2019-09-30 Avon Prod Inc Composiciones estimuladoras de paxilina y usos cosmeticos de las mismas.
US20110159125A1 (en) 2009-12-29 2011-06-30 Avon Products, Inc. CGRP Compositions and Uses Thereof
FR2992315B1 (fr) * 2012-06-25 2014-08-08 Pf Medicament Derives utiles dans le traitement de maladies du systeme nerveux central
EP2919788A4 (fr) 2012-11-14 2016-05-25 Univ Johns Hopkins Méthodes et compositions pour le traitement de la schizophrénie
CN102952134B (zh) * 2012-12-05 2015-01-07 苏州药明康德检测检验有限责任公司 含二氟甲基的金雀花碱衍生物及制备方法和抗癌作用研究
RU2630958C2 (ru) * 2015-12-29 2017-09-15 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" (МФТИ) Новые макроциклические соединения, содержащие природное 3,7-диазабицикло[3.3.1]нонановое ядро и способ их получения
GB201602145D0 (en) 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
AU2017313390A1 (en) * 2016-08-19 2019-03-07 The University Of Bristol Cytisine derivatives for the treatment of addiction
JP7178158B2 (ja) 2017-07-24 2022-11-25 アチーブ ファーマ ユーケイ リミテッド シチシン塩、シチシン塩の溶媒和物または水和物、シチシン塩の製造方法、医薬組成物、および治療方法
CN114727647A (zh) * 2019-09-12 2022-07-08 阿奇维生命科学公司 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3332429T1 (de) * 1982-02-22 1984-01-26 Belorusskij naučno-issledovatel'skij sanitarno-gigieničeskij institut, 220012 Minsk Arzneipraeparat mit antinikotinwirkung und verfahren zu seiner herstellung
US4835162A (en) 1987-02-12 1989-05-30 Abood Leo G Agonists and antagonists to nicotine as smoking deterents
US5242916A (en) * 1992-07-07 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
TW261531B (fr) * 1993-10-28 1995-11-01 Dynagen Inc
WO1997011072A1 (fr) * 1995-09-22 1997-03-27 Novo Nordisk A/S Nouveaux composes azacycliques ou azabicycliques a substitution

Also Published As

Publication number Publication date
EP0937077A1 (fr) 1999-08-25
JP2000505809A (ja) 2000-05-16
EP0937077B1 (fr) 2006-05-17
JP3621707B2 (ja) 2005-02-16
HRP970567A2 (en) 1998-10-31
US6235734B1 (en) 2001-05-22
ATE326468T1 (de) 2006-06-15
AP9701125A0 (en) 1997-10-31
AU4394897A (en) 1998-05-22
MA26445A1 (fr) 2004-12-20
WO1998018798A1 (fr) 1998-05-07
PA8440201A1 (es) 2000-05-24
US20030065173A1 (en) 2003-04-03
ID18741A (id) 1998-05-07
JP2005060403A (ja) 2005-03-10
DE69735891D1 (de) 2006-06-22
AR008901A1 (es) 2000-02-23
TNSN97168A1 (fr) 2005-03-15
ES2264169T3 (es) 2006-12-16
US6630467B2 (en) 2003-10-07
GT199700115A (es) 1999-04-20
DE69735891T2 (de) 2006-12-14

Similar Documents

Publication Publication Date Title
ZA979706B (en) Nicotinic agents in addiction theraphy
HRP970330A2 (en) Cycloalkano pyridines
SG46782A1 (en) Bicyclic-fused pyridines
AP9801175A0 (en) Quinoline and quinoline compounds useful in therapy
DE69927412D1 (en) Phosphitadditive in polyolefinen
PL335258A1 (en) Arylamine-condensed pyridines and pyrimidines
HK1045639B (zh) 滑動復原設備
PL327610A1 (en) Quinoline and quinozoline compounds useful in therapy
GB9717766D0 (en) Methods
GB2320435B (en) Improvements in Magnotherapy
IL136754A0 (en) Improvements in hosiery
GB9822063D0 (en) Hinge suitable for use in afoldable device
HUP0001110A3 (en) 3-pyridyl enantiomers and their use as analgesics
GB9412294D0 (en) Improvements in cutting devices
DE69732623D1 (en) Analogsignalmultiplexer in strombetriebsart
GB2321857B (en) Improvements in filters
IL123453A0 (en) Combination preparation for use in dementia
GB9725953D0 (en) Compounds useful in therapy
GB9707742D0 (en) Methods
GB9718591D0 (en) Methods
PL339259A1 (en) Gonadothropin expression in dictostelium
DE69531611D1 (en) Lactone-stabile camptothecin oder 7 - ethyl camptothecin - formulierung in dimethylisosorbid oder dimethylacetamid
GB9602100D0 (en) Decals
GB9706332D0 (en) Improvements in aprons
GB9504832D0 (en) Improvements in lockig means